Ah Young-Mi, Lee Ju-Yeun, Choi Yun-Jung, Kim Baegeum, Choi Kyung Hee, Kong Jisun, Oh Jung Mi, Shin Wan Gyoon, Lee Hae-Young
College of Pharmacy, Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan, Korea.
College of Pharmacy, Sunchon National University, Suncheon, Korea.
J Korean Med Sci. 2015 Dec;30(12):1800-6. doi: 10.3346/jkms.2015.30.12.1800. Epub 2015 Nov 30.
We aimed to assess one-year persistence with antihypertensive therapy (AHT) among newly treated uncomplicated hypertensive patients in Korea and to evaluate the effect of initial therapeutic classes on persistence. We retrospectively analyzed a random sample of 20% of newly treated uncomplicated hypertensive patients (n = 45,787) in 2012 from the National Health Insurance claims database. This group was classified into six cohorts based on initial AHT class. We then measured treatment persistence, allowing a prescription gap of 60 days. Adherence to AHT was assessed with the medication possession ratio. Calcium channel blockers (CCB, 43.7%) and angiotensin receptor blockers (ARB, 40.3%) were most commonly prescribed as initial monotherapy. Overall, 62.1% and 42.0% were persistent with any AHT and initial class at one year, respectively, and 64.2% were adherent to antihypertensive treatment. Compared with ARBs, the risk of AHT discontinuation was significantly increased with initial use of thiazide diuretics (hazard ratio [HR], 3.16; 95% confidence interval [CI] 2.96-3.74) and beta blockers (HR, 1.86; CI, 1.77-1.95) and was minimally increased with CCBs (HR, 1.12; CI, 1.08-1.15). In conclusion, persistence and adherence to AHT are suboptimal, but the differences are meaningful in persistence and adherence between initial AHT classes.
我们旨在评估韩国新治疗的无并发症高血压患者中抗高血压治疗(AHT)的一年持续性,并评估初始治疗类别对持续性的影响。我们回顾性分析了2012年从国家健康保险理赔数据库中随机抽取的20%新治疗的无并发症高血压患者样本(n = 45,787)。该组根据初始AHT类别分为六个队列。然后我们测量了治疗持续性,允许有60天的处方间隔。通过药物持有率评估对AHT的依从性。钙通道阻滞剂(CCB,43.7%)和血管紧张素受体阻滞剂(ARB,40.3%)是最常用的初始单药治疗药物。总体而言,一年时分别有62.1%和42.0%的患者持续接受任何AHT和初始治疗类别,64.2%的患者坚持抗高血压治疗。与ARB相比,初始使用噻嗪类利尿剂(风险比[HR],3.16;95%置信区间[CI] 2.96 - 3.74)和β受体阻滞剂(HR,1.86;CI,1.77 - 1.95)时AHT停药风险显著增加,而CCB导致的风险略有增加(HR,1.12;CI,1.08 - 1.15)。总之,AHT的持续性和依从性不理想,但初始AHT类别之间在持续性和依从性方面的差异具有意义。